Inovio Pharmaceuticals Announces Public Offering of Common Stock
April 29 2015 - 4:01PM
Inovio Pharmaceuticals, Inc. (Nasdaq:INO) ("Inovio" or the
"Company"), today announced that it intends to offer and sell
shares of its common stock in an underwritten public offering.
Piper Jaffray & Co. and Stifel are acting as joint bookrunning
managers for the offering. The offering is subject to market
conditions, and there can be no assurance as to whether or when the
offering may be completed, or as to the actual size or terms of the
offering.
The securities described above are being offered by the Company
pursuant to a shelf registration statement previously filed with
and declared effective by the Securities and Exchange Commission on
August 8, 2014. The offering will be made only by means of the
written prospectus and prospectus supplement that form a part of
the registration statement. Copies of the preliminary prospectus
supplement and the accompanying prospectus relating to the
securities being offered may also be obtained from Piper Jaffray
& Co., Attention: Prospectus Department, 800 Nicollet Mall,
J12S03, Minneapolis, MN 55402, via telephone at 800-747-3924 or
email at prospectus@pjc.com; or from Stifel, Nicolaus &
Company, Incorporated, Attention: Syndicate, One Montgomery Street,
Suite 3700, San Francisco, CA 94104, via telephone at 415-364-2720
or email at syndprospectus@stifel.com.
This press release does not constitute an offer to sell
or the solicitation of offers to buy any
securities of Inovio being
offered, and shall not constitute an offer,
solicitation or sale of any security in any state
or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or
qualification under the securities laws of any such state
or jurisdiction.
About Inovio Pharmaceuticals, Inc.
Inovio is revolutionizing the fight against cancer and
infectious diseases. Our immunotherapies uniquely activate
best-in-class immune responses to prevent and treat disease, and
have shown clinically significant efficacy with a favorable safety
profile. With an expanding portfolio of immune therapies, the
company is advancing a growing preclinical and clinical stage
product pipeline. Partners and collaborators include Roche,
MedImmune, University of Pennsylvania, DARPA, Drexel University,
NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S.
Military HIV Research Program, and University of Manitoba. For more
information, visit www.inovio.com. This press release contains
certain forward-looking statements under the Private Securities
Litigation Reform Act of 1995 relating to our business, including
our plans to develop electroporation-based drug and gene delivery
technologies and DNA vaccines, our expectations regarding our
research and development programs and our capital resources. Actual
events or results may differ from the expectations set forth herein
as a result of a number of factors, including that the offering is
subject to market conditions, and there can be no assurance as to
whether or when the offering may be completed, or as to the actual
size or terms of the offering, and uncertainties inherent in
pre-clinical studies, clinical trials and product development
programs (including, but not limited to, the fact that pre-clinical
and clinical results referenced in this release may not be
indicative of results achievable in other trials or for other
indications, that the studies or trials may not be successful or
achieve the results desired, including safety and efficacy for
VGX-3100, that pre-clinical studies and clinical trials may not
commence or be completed in the time periods anticipated, that
results from one study may not necessarily be reflected or
supported by the results of other similar studies and that results
from an animal study may not be indicative of results achievable in
human studies), the availability of funding to support continuing
research and studies in an effort to prove safety and efficacy of
electroporation technology as a delivery mechanism or develop
viable DNA vaccines, our ability to support our broad pipeline of
SynCon® active immune therapy and vaccine products, our ability to
advance our portfolio of immune-oncology products independently,
including INO-5150, and to commence a phase I clinical trial for
INO-5150 in the first half of 2015, the adequacy of our capital
resources, the availability or potential availability of
alternative therapies or treatments for the conditions targeted by
the company or its collaborators, including alternatives that may
be more efficacious or cost-effective than any therapy or treatment
that the company and its collaborators hope to develop, our ability
to enter into partnerships in conjunction with our research and
development programs, evaluation of potential opportunities, issues
involving product liability, issues involving patents and whether
they or licenses to them will provide the company with meaningful
protection from others using the covered technologies, whether such
proprietary rights are enforceable or defensible or infringe or
allegedly infringe on rights of others or can withstand claims of
invalidity and whether the company can finance or devote other
significant resources that may be necessary to prosecute, protect
or defend them, the level of corporate expenditures, assessments of
the company's technology by potential corporate or other partners
or collaborators, capital market conditions, the impact of
government healthcare proposals and other factors set forth in our
Annual Report on Form 10-K for the year ended December 31, 2014,
and other regulatory filings from time to time. There can be no
assurance that any product in Inovio's pipeline will be
successfully developed or manufactured, that final results of
clinical studies will be supportive of regulatory approvals
required to market licensed products, or that any of the
forward-looking information provided herein will be proven
accurate.
CONTACT: Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Sep 2023 to Sep 2024